Výsledky vyhledávání - "Southward, K"

HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials

Autor: Richman, SD, Southward, K, Chambers, P, Cross, D, Barrett, J, Hemmings, G, Taylor, M, Wood, H, Hutchins, G, Foster, JM, Oumie, A, Spink, KG, Brown, SR, Jones, M, Kerr, D, Handley, K, Gray, R, Seymour, M, Quirke, P

Publikováno v: The Journal of Pathology
Europe PubMed Central

HER2 overexpression/amplification is linked to trastuzumab response in breast/gastric cancers. One suggested anti‐EGFR resistance mechanism in colorectal cancer (CRC) is aberrant MEK–AKT pathway activation through HER2 up‐regulation. We assesse

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::e3ead3a0d84a04bc342fabbf873b8aab
http://europepmc.org/articles/PMC4785607

Zobrazit plný text záznamu

Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations

Background: The influence of EGFR pathway mutations on cetuximab-containing rectal cancer preoperative chemoradiation (CRT) is uncertain. Methods: In a prospective phase II trial (EXCITE), patients with magnetic resonance imaging (MRI)-defined non-me

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::befe42e223d85a48a82ff06071c5457d
https://eprints.whiterose.ac.uk/120885/12/bjc2017294a.pdf

Zobrazit plný text záznamu

Intra-tumoural stromal morphometry predicts disease recurrence but not response to 5-fluorouracil - results from the QUASAR trial of colorectal cancer

Autor: Hutchins, GGA, Treanor, D, Wright, A, Handley, K, Magill, L, Tinkler-Hundal, E, Southward, K, Seymour, M, Kerr, D, Gray, R, Quirke, P, QUASAR trial collaborators

Publikováno v: Histopathology. 72(3)

INTRODUCTION: The biological importance of tumour-associated stroma is increasingly apparent, yet clinical utility remains ill-defined. In stage-II / Dukes B colorectal cancer (CRC), clinical biomarkers are urgently required to direct therapeutic opt

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f9a5bca621a5b3f1889f9762d5e5d18
http://ora.ox.ac.uk/objects/uuid:

Zobrazit plný text záznamu